The upgrade in the price target by a reputable analyst like Yigal Nochomovitz from Citigroup is a strong positive signal for Rigel Pharmaceuticals. It suggests a bullish outlook on the stock, likely due to positive developments within the company or its market potential. This can lead to increased investor confidence and potentially drive the stock price up in the short term.